{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T02:02:39Z","timestamp":1791079359274,"version":"4.1.0"},"reference-count":107,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,2]],"date-time":"2015-12-02T00:00:00Z","timestamp":1449014400000},"content-version":"vor","delay-in-days":2740,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1097\/jto.0b013e318174ea3a","type":"journal-article","created":{"date-parts":[[2010,1,27]],"date-time":"2010-01-27T06:04:45Z","timestamp":1264572285000},"page":"S152-S159","source":"Crossref","is-referenced-by-count":61,"special_numbering":"S2","title":["Heat Shock Protein 90 Inhibition in Lung Cancer"],"prefix":"10.1016","volume":"3","author":[{"given":"Takeshi","family":"Shimamura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey I.","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1097\/JTO.0b013e318174ea3a_bib1","doi-asserted-by":"crossref","first-page":"420","DOI":"10.3181\/00379727-217-44252","article-title":"The hsp90-based chaperone system: involvement in signal transduction from a variety of hormone and growth factor receptors","volume":"217","author":"Pratt","year":"1998","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib2","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/nrc1716","article-title":"HSP90 and the chaperoning of cancer","volume":"5","author":"Whitesell","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib3","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3109\/07853899708998745","article-title":"Heat shock response: pathophysiological implications","volume":"29","author":"Leppa","year":"1997","journal-title":"Ann Med"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib4","doi-asserted-by":"crossref","first-page":"16580","DOI":"10.1074\/jbc.270.28.16580","article-title":"Herbimycin A induces the 20 S proteasome- and ubiquitin-dependent degradation of receptor tyrosine kinases","volume":"270","author":"Sepp-Lorenzino","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib5","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.molmed.2003.12.005","article-title":"Altered states: selectively drugging the Hsp90 cancer chaperone","volume":"10","author":"Workman","year":"2004","journal-title":"Trends Mol Med"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib6","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1093\/jnci\/92.19.1564","article-title":"Role of the heat shock response and molecular chaperones in oncogenesis and cell death","volume":"92","author":"Jolly","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib7","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1126\/science.1073096","article-title":"Addiction to oncogenes-the Achilles heal of cancer","volume":"297","author":"Weinstein","year":"2002","journal-title":"Science"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib8","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1158\/1078-0432.CCR-06-2966","article-title":"Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells","volume":"13","author":"Xu","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib9","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2174\/156800907780809778","article-title":"Hsp90: a novel target for the disruption of multiple signaling cascades","volume":"7","author":"Bishop","year":"2007","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib10","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1073\/pnas.96.1.109","article-title":"Maturation of the tyrosine kinase c-src as a kinase and as a substrate depends on the molecular chaperone Hsp90","volume":"96","author":"Xu","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib11","doi-asserted-by":"crossref","first-page":"10686","DOI":"10.1158\/0008-5472.CAN-05-2632","article-title":"Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin","volume":"65","author":"da Rocha Dias","year":"2005","journal-title":"Cancer Res"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib12","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1073\/pnas.0609973103","article-title":"V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors","volume":"103","author":"Grbovic","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib13","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/nature01913","article-title":"A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors","volume":"425","author":"Kamal","year":"2003","journal-title":"Nature"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib14","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00280-001-0380-8","article-title":"Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats","volume":"49","author":"Egorin","year":"2002","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib15","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1023\/A:1025542026488","article-title":"Physiologically-based pharmacokinetics and molecular pharmacodynamics of 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite in tumor-bearing mice","volume":"30","author":"Xu","year":"2003","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib16","doi-asserted-by":"crossref","first-page":"6401","DOI":"10.1158\/0008-5472.CAN-05-0933","article-title":"Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins","volume":"65","author":"Shimamura","year":"2005","journal-title":"Cancer Res"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib17","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1200\/JCO.2005.09.985","article-title":"Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology","volume":"23","author":"Janne","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib18","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to Gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib19","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib20","doi-asserted-by":"crossref","first-page":"13306","DOI":"10.1073\/pnas.0405220101","article-title":"EGF receptor gene mutations are common in lung cancers from \u201cnever smokers\u201d and are associated with sensitivity of tumors to gefitinib and erlotinib","volume":"101","author":"Pao","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib21","doi-asserted-by":"crossref","first-page":"6990","DOI":"10.1158\/0008-5472.CAN-06-1042","article-title":"Association with HSP90 inhibits Cbl-mediated down-regulation of mutant epidermal growth factor receptors","volume":"66","author":"Yang","year":"2006","journal-title":"Cancer Res"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib22","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1074\/jbc.M006864200","article-title":"Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90","volume":"276","author":"Xu","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib23","doi-asserted-by":"crossref","first-page":"e313","DOI":"10.1371\/journal.pmed.0020313","article-title":"Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants","volume":"2","author":"Greulich","year":"2005","journal-title":"PLoS Med"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib24","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/sj.bjc.6603950","article-title":"Sensitivity of epidermal growth factor receptor and ErbB2 exon 20 insertion mutants to Hsp90 inhibition","volume":"97","author":"Xu","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib25","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1056\/NEJMoa044238","article-title":"EGFR mutation and resistance of non-small-cell lung cancer to gefitinib","volume":"352","author":"Kobayashi","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib26","first-page":"1","article-title":"Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain","volume":"2","author":"Pao","year":"2005","journal-title":"PLoS Med"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib27","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1158\/0008-5472.CAN-06-4293","article-title":"Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib","volume":"67","author":"Mulloy","year":"2007","journal-title":"Cancer Res"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib28","doi-asserted-by":"crossref","first-page":"7096","DOI":"10.1158\/0008-5472.CAN-05-1346","article-title":"An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor","volume":"65","author":"Kobayashi","year":"2005","journal-title":"Cancer Res"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib29","doi-asserted-by":"crossref","first-page":"7665","DOI":"10.1073\/pnas.0502860102","article-title":"Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib","volume":"102","author":"Kwak","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib30","doi-asserted-by":"crossref","first-page":"11011","DOI":"10.1073\/pnas.0504952102","article-title":"Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases","volume":"102","author":"Carter","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib31","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ccr.2007.06.005","article-title":"Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy","volume":"12","author":"Li","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib32","doi-asserted-by":"crossref","first-page":"e810","DOI":"10.1371\/journal.pone.0000810","article-title":"Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors","volume":"2","author":"Regales","year":"2007","journal-title":"PLoS ONE"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib33","doi-asserted-by":"crossref","first-page":"A3018","DOI":"10.1200\/jco.2006.24.18_suppl.3018","article-title":"HKI-272, an irreversible pan erbB receptor tyrosine kinase inhibitor: preliminary phase I results in patients with solid tumors (abstract)","volume":"24","author":"Wong","year":"2006","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib34","doi-asserted-by":"crossref","first-page":"39858","DOI":"10.1074\/jbc.M206322200","article-title":"Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function","volume":"277","author":"Basso","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib35","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/jb\/mvj008","article-title":"Suppression of the mTOR-raptor signaling pathway by the inhibitor of heat shock protein 90 geldanamycin","volume":"139","author":"Ohji","year":"2006","journal-title":"J Biochem (Tokyo)"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib36","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-07-5428","article-title":"Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor release","author":"Shimamura","year":"2008","journal-title":"Cancer Res"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib37","doi-asserted-by":"crossref","first-page":"7817","DOI":"10.1073\/pnas.0510284103","article-title":"Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors","volume":"103","author":"Ji","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib38","doi-asserted-by":"crossref","first-page":"5292","DOI":"10.1074\/jbc.M209494200","article-title":"Interaction of Hsp90 with the nascent form of the mutant epidermal growth factor receptor EGFRvIII","volume":"278","author":"Lavictoire","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib39","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/431525b","article-title":"Lung cancer: intragenic ERBB2 kinase mutations in tumours","volume":"431","author":"Stephens","year":"2004","journal-title":"Nature"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib40","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1158\/0008-5472.CAN-04-4235","article-title":"Somatic mutations of the HER2 kinase domain in lung adenocarcinomas","volume":"65","author":"Shigematsu","year":"2005","journal-title":"Cancer Res"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib41","doi-asserted-by":"crossref","first-page":"6487","DOI":"10.1158\/0008-5472.CAN-06-0971","article-title":"Non-small-cell lung cancer and Ba\/F3 transformed cells harboring the ERBB2 G776insV_G\/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272","volume":"66","author":"Shimamura","year":"2006","journal-title":"Cancer Res"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib42","first-page":"342","article-title":"The geldanamycins are potent inhibitors of the hepatocyte growth factor\/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network","volume":"60","author":"Webb","year":"2000","journal-title":"Cancer Res"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib43","doi-asserted-by":"crossref","first-page":"4960","DOI":"10.1016\/j.bmc.2005.05.038","article-title":"Geldanamycin derivative inhibition of HGF\/SF-mediated Met tyrosine kinase receptor-dependent urokinase-plasminogen activation","volume":"13","author":"Shen","year":"2005","journal-title":"Bioorg Med Chem"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib44","first-page":"620","article-title":"Modulation of the c-Met\/Hepatocyte growth factor pathway in small cell lung cancer","volume":"8","author":"Maulik","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib45","first-page":"6997","article-title":"BRAF and RAS mutations in human lung cancer and melanoma","volume":"62","author":"Brose","year":"2002","journal-title":"Cancer Res"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib46","first-page":"7001","article-title":"Missense mutations of the BRAF gene in human lung adenocarcinoma","volume":"62","author":"Naoki","year":"2002","journal-title":"Cancer Res"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib47","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1158\/0008-5472.CAN-04-2650","article-title":"Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer","volume":"65","author":"Ma","year":"2005","journal-title":"Cancer Res"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib48","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1158\/0008-5472.CAN-05-2749","article-title":"Somatic mutations lead to an oncogenic deletion of met in lung cancer","volume":"66","author":"Kong-Beltran","year":"2006","journal-title":"Cancer Res"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib49","doi-asserted-by":"crossref","first-page":"5561","DOI":"10.1158\/0008-5472.CAN-04-4603","article-title":"Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis","volume":"65","author":"Zhao","year":"2005","journal-title":"Cancer Res"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib50","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1158\/0008-5472.CAN-06-3495","article-title":"Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival","volume":"67","author":"Lutterbach","year":"2007","journal-title":"Cancer Res"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib51","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1073\/pnas.0508776103","article-title":"Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752","volume":"103","author":"Smolen","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib52","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1141478","article-title":"MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling","volume":"316","author":"Engelman","year":"2007","journal-title":"Science"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib53","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/gcc.20122","article-title":"CDK4 is a probable target gene in a novel amplicon at 12q13. 3-q14. 1 in lung cancer","volume":"42","author":"Wikman","year":"2005","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib54","doi-asserted-by":"crossref","first-page":"10100","DOI":"10.1158\/0008-5472.CAN-06-1684","article-title":"Heterodimerization of insulin-like growth factor receptor\/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib","volume":"66","author":"Morgillo","year":"2006","journal-title":"Cancer Res"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib55","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2005-03-1158","article-title":"Antimyeloma activity of heat shock protein-90 inhibition","volume":"107","author":"Mitsiades","year":"2006","journal-title":"Blood"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib56","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S0168-9525(03)00073-8","article-title":"Class II histone deacetylases: versatile regulators","volume":"19","author":"Verdin","year":"2003","journal-title":"Trends Genet"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib57","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/417455a","article-title":"HDAC6 is a microtubule-associated deacetylase","volume":"417","author":"Hubbert","year":"2002","journal-title":"Nature"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib58","doi-asserted-by":"crossref","first-page":"26729","DOI":"10.1074\/jbc.C500186200","article-title":"Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors","volume":"280","author":"Bali","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib59","doi-asserted-by":"crossref","first-page":"5468","DOI":"10.1038\/sj.onc.1210614","article-title":"HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination","volume":"26","author":"Boyault","year":"2007","journal-title":"Oncogene"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib60","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0092-8674(03)00939-5","article-title":"The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress","volume":"115","author":"Kawaguchi","year":"2003","journal-title":"Cell"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib61","first-page":"5126","article-title":"Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells","volume":"63","author":"Nimmanapalli","year":"2003","journal-title":"Cancer Res"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib62","first-page":"971","article-title":"Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B","volume":"2","author":"Fuino","year":"2003","journal-title":"Mol Cancer Ther"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib63","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1182\/blood-2004-09-3413","article-title":"Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3","volume":"105","author":"George","year":"2005","journal-title":"Blood"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib64","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1158\/1535-7163.MCT-06-0761","article-title":"Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells","volume":"6","author":"Edwards","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib65","doi-asserted-by":"crossref","first-page":"745","DOI":"10.4161\/cbt.5.7.2971","article-title":"Proteasome inhibitor induces apoptosis through induction of endoplasmic reticulum stress","volume":"5","author":"Fribley","year":"2006","journal-title":"Cancer Biol Ther"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib66","doi-asserted-by":"crossref","first-page":"11658","DOI":"10.1158\/0008-5472.CAN-05-2370","article-title":"Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis","volume":"65","author":"Nawrocki","year":"2005","journal-title":"Cancer Res"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib67","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","article-title":"Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells","volume":"107","author":"Obeng","year":"2006","journal-title":"Blood"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib68","first-page":"215","article-title":"Review. The endoplasmic reticulum: a target for new anticancer drugs","volume":"21","author":"Boelens","year":"2007","journal-title":"In Vivo"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib69","doi-asserted-by":"crossref","first-page":"5025","DOI":"10.1200\/JCO.2006.06.1853","article-title":"Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer","volume":"24","author":"Fanucchi","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib70","doi-asserted-by":"crossref","first-page":"579","DOI":"10.4161\/cc.2.6.521","article-title":"HSP27 and HSP70: potentially oncogenic apoptosis inhibitors","volume":"2","author":"Garrido","year":"2003","journal-title":"Cell Cycle"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib71","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.4161\/cc.5.22.3448","article-title":"Heat shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties","volume":"5","author":"Garrido","year":"2006","journal-title":"Cell Cycle"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib72","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/ncb0901-839","article-title":"Heat-shock protein 70 antagonizes apoptosis-inducing factor","volume":"3","author":"Ravagnan","year":"2001","journal-title":"Nat Cell Biol"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib73","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/35019510","article-title":"Negative regulation of the Apaf-1 apoptosome by Hsp70","volume":"2","author":"Saleh","year":"2000","journal-title":"Nat Cell Biol"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib74","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/35019501","article-title":"Heat-shock protein 70 inhibits apoptosis by preventing recruitment of procaspase-9 to the Apaf-1 apoptosome","volume":"2","author":"Beere","year":"2000","journal-title":"Nat Cell Biol"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib75","doi-asserted-by":"crossref","first-page":"10536","DOI":"10.1158\/0008-5472.CAN-05-1799","article-title":"Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin","volume":"65","author":"Guo","year":"2005","journal-title":"Cancer Res"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib76","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1097-2765(03)00526-4","article-title":"Coordination of transcription, RNA processing, and surveillance by P-TEFb kinase on heat shock genes","volume":"13","author":"Ni","year":"2004","journal-title":"Mol Cell"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib77","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.gene.2004.05.007","article-title":"Cellular control of gene expression by T-type cyclin\/CDK9 complexes","volume":"337","author":"Garriga","year":"2004","journal-title":"Gene"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib78","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1200\/JCO.2005.03.7689","article-title":"Cyclin-dependent kinase pathways as targets for cancer treatment","volume":"24","author":"Shapiro","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib79","doi-asserted-by":"crossref","first-page":"28345","DOI":"10.1074\/jbc.C000446200","article-title":"Flavopiridol inhibits P-TEFb and blocks HIV-1 replication","volume":"275","author":"Chao","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib80","doi-asserted-by":"crossref","first-page":"31793","DOI":"10.1074\/jbc.M102306200","article-title":"Flavopiridol inactivates p-TEFb and blocks most RNA polymerase II transcription in vivo","volume":"276","author":"Chao","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib81","doi-asserted-by":"crossref","DOI":"10.1186\/gb-2001-2-10-research0041","article-title":"Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol","volume":"2","author":"Lam","year":"2001","journal-title":"Genome Biol"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib82","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1038\/sj.cdd.4401812","article-title":"Pharmacological induction of Hsp70 protects apoptosis-prone cells from doxorubicin: comparison with caspase-inhibitor- and cycle-arrest-mediated cytoprotection","volume":"13","author":"Demidenko","year":"2006","journal-title":"Cell Death Differ"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib83","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/nchembio.2007.10","article-title":"Selective compounds define Hsp90 as a major inhibitor of apoptosis in small-cell lung cancer","volume":"3","author":"Rodina","year":"2007","journal-title":"Nat Chem Biol"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib84","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2174\/1568009033481831","article-title":"Clinical development of 17-allylamino, 17-demethoxygeldanamycin","volume":"3","author":"Sausville","year":"2003","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib85","doi-asserted-by":"crossref","first-page":"4152","DOI":"10.1200\/JCO.2005.00.612","article-title":"Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies","volume":"23","author":"Banerji","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib86","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1200\/JCO.2005.09.119","article-title":"Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer","volume":"23","author":"Goetz","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib87","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1158\/1078-0432.CCR-04-2322","article-title":"Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers","volume":"11","author":"Ramanathan","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib88","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1200\/JCO.2005.12.085","article-title":"Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors","volume":"23","author":"Grem","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib89","doi-asserted-by":"crossref","first-page":"6087","DOI":"10.1158\/1078-0432.CCR-06-1015","article-title":"A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer","volume":"12","author":"Nowakowski","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib90","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1158\/1078-0432.CCR-06-2233","article-title":"Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers","volume":"13","author":"Ramanathan","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib91","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1158\/1078-0432.CCR-06-1863","article-title":"Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer","volume":"13","author":"Solit","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib92","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1158\/1078-0432.CCR-06-1892","article-title":"Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study","volume":"13","author":"Bagatell","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib93","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1158\/1078-0432.CCR-06-2270","article-title":"A phase I study of 17-allylaminogeldanamycin in relapsed\/refractory pediatric patients with solid tumors: a Children's Oncology Group study","volume":"13","author":"Weigel","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib94","doi-asserted-by":"crossref","first-page":"5317","DOI":"10.1016\/j.bmc.2004.07.053","article-title":"Synthesis and biological activities of novel 17-aminogeldanamycin derivatives","volume":"12","author":"Tian","year":"2004","journal-title":"Bioorg Med Chem"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib95","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00280-004-0865-3","article-title":"Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]-geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts","volume":"55","author":"Eiseman","year":"2005","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib96","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s00280-004-0947-2","article-title":"Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models","volume":"56","author":"Smith","year":"2005","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib97","doi-asserted-by":"crossref","first-page":"4606","DOI":"10.1021\/jm0603116","article-title":"Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90","volume":"49","author":"Ge","year":"2006","journal-title":"J Med Chem"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib98","doi-asserted-by":"crossref","first-page":"17408","DOI":"10.1073\/pnas.0608372103","article-title":"Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90","volume":"103","author":"Sydor","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib99","doi-asserted-by":"crossref","first-page":"500","DOI":"10.3816\/CLM.2006.n.034","article-title":"17-dimethylaminoethylamino-17-demethoxygeldanamycin in patients with advanced-stage solid tumors and lymphoma: a phase I study","volume":"6","author":"Shadad","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib100","doi-asserted-by":"crossref","first-page":"A13148","DOI":"10.1200\/jco.2006.24.18_suppl.13148","article-title":"Interim analysis of phase I trial of 17-DMAG (abstract)","volume":"24","author":"Cartwright","year":"2006","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib101","doi-asserted-by":"crossref","first-page":"A2081","DOI":"10.1200\/jco.2006.24.18_suppl.2081","article-title":"Phase 1, pharmacokinetic (PK) and pharmacodynamic (PD) study of the Hsp90 inhibitor KOS-1022 (17-DMAG) in patients with refractory hemtological malignancies (abstract)","volume":"24","author":"Lancet","year":"2006","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib102","first-page":"A570","article-title":"Overcoming resistance to tyrosine kinase inhibitors (TKIs) through inhibition of Heat Shock Protein (Hsp90) chaperone function in patients with metastatic GIST: results of a Phase I Trial of IPI-504, a water-soluble Hsp90 inhibitor (abstract)","volume":"4","author":"Demetri","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib103","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1200\/JCO.2007.11.7960","article-title":"Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study","volume":"25","author":"Modi","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib104","first-page":"B29","article-title":"Phase I\/II trial of the novel Hsp90 inhibitor, IPI-504, inpatients with relapsed and\/or refractory stage IIIB or stage IV non-small cell lung cancer stratified by EGFR mutation status (abstract)","author":"Sequist","year":"2007","journal-title":"Proc AACR-NCI-EORTC"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib105","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0065-230X(06)95009-X","article-title":"Inhibitors of the HSP90 molecular chaperone: current status","volume":"95","author":"Sharp","year":"2006","journal-title":"Adv Cancer Res"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib106","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1016\/S0968-0896(02)00253-5","article-title":"Development of a purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of Her2 tyrosine kinase","volume":"10","author":"Chiosis","year":"2002","journal-title":"Bioorg Med Chem"},{"key":"10.1097\/JTO.0b013e318174ea3a_bib107","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1021\/jm701018h","article-title":"4,5-Diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer","volume":"51","author":"Brough","year":"2008","journal-title":"J Med Chem"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415331245?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415331245?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T02:16:24Z","timestamp":1590545784000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086415331245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":107,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["S1556086415331245"],"URL":"https:\/\/doi.org\/10.1097\/jto.0b013e318174ea3a","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2008,6]]}}}